Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$109.39 +4.0%	$105.71	$75.56 ▼ $139.13	$5.25B	0.51	630,955 shs	589,197 shs
JANX Janux Therapeutics	$24.96 +2.8%	$24.62	$21.97 ▼ $71.71	$1.46B	2.86	870,620 shs	1.72 million shs
LNTH Lantheus	$53.79 -0.2%	$74.90	$47.25 ▼ $118.21	$3.66B	0.14	2.16 million shs	2.33 million shs
TGTX TG Therapeutics	$27.87 +2.8%	$35.54	$20.39 ▼ $46.48	$4.30B	1.95	2.76 million shs	2.70 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.22%	+1.58%	-3.44%	+1.50%	+23.92%
JANX Janux Therapeutics	+7.06%	-4.82%	-3.50%	+7.29%	-33.69%
LNTH Lantheus	-3.87%	-25.79%	-33.71%	-31.61%	-44.24%
TGTX TG Therapeutics	+2.77%	-4.51%	-26.86%	-18.80%	+31.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8383 of 5 stars	4.5	3.0	4.5	2.4	4.2	0.6
JANX Janux Therapeutics	2.5117 of 5 stars	3.5	2.0	0.0	2.2	3.3	0.0
LNTH Lantheus	4.8622 of 5 stars	4.4	3.0	4.2	2.9	2.5	1.9
TGTX TG Therapeutics	4.2046 of 5 stars	3.4	0.0	3.5	3.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	62.72% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	268.14% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	96.13% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	65.95% Upside

Current Analyst Ratings Breakdown

Latest JANX, TGTX, AXSM, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.15	N/A	N/A	$1.46 per share	74.92
JANX Janux Therapeutics	$10.59M	141.63	N/A	N/A	$16.48 per share	1.51
LNTH Lantheus	$1.53B	2.38	$7.08 per share	7.60	$17.16 per share	3.13
TGTX TG Therapeutics	$329M	13.44	$0.12 per share	226.07	$1.74 per share	16.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	38.79	N/A	-49.88%	-283.22%	-33.06%	N/A
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	N/A
LNTH Lantheus	$312.44M	$3.76	14.31	8.52	N/A	17.82%	34.06%	19.10%	N/A
TGTX TG Therapeutics	$23.38M	$0.37	75.32	27.87	N/A	13.31%	26.05%	9.58%	N/A

Latest JANX, TGTX, AXSM, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
JANX Janux Therapeutics	N/A	47.03	47.03
LNTH Lantheus	0.49	4.29	4.07
TGTX TG Therapeutics	0.89	3.86	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JANX Janux Therapeutics	75.39%
LNTH Lantheus	99.06%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
JANX Janux Therapeutics	8.10%
LNTH Lantheus	1.50%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
TGTX TG Therapeutics	290	158.67 million	141.78 million	Optionable

JANX, TGTX, AXSM, and LNTH Headlines

Recent News About These Companies

Persistent Asset Partners Ltd Has $1.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 13 at 7:05 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Public Sector Pension Investment Board

August 13 at 5:44 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Entropy Technologies LP

August 13 at 4:57 AM | marketbeat.com

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10 at 7:35 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10 at 3:50 AM | marketbeat.com

What is B. Riley's Estimate for TG Therapeutics Q3 Earnings?

August 9, 2025 | americanbankingnews.com

TG Therapeutics files automatic mixed securities shelf

August 9, 2025 | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8, 2025 | gurufocus.com

What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

August 8, 2025 | marketbeat.com

What is B. Riley's Forecast for TG Therapeutics Q4 Earnings?

August 8, 2025 | americanbankingnews.com

FY2025 EPS Estimate for TG Therapeutics Reduced by Analyst

August 8, 2025 | americanbankingnews.com

B. Riley Has Bullish Outlook for TG Therapeutics Q4 Earnings

August 7, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings

August 7, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $43.80 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook

August 6, 2025 | msn.com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

August 6, 2025 | msn.com

Federated Hermes Inc. Sells 64,385 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

August 6, 2025 | marketbeat.com

Investors Purchase High Volume of Call Options on TG Therapeutics (NASDAQ:TGTX)

August 6, 2025 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Gap Down Following Weak Earnings

August 6, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

August 5, 2025 | insidermonkey.com

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

August 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, TGTX, AXSM, and LNTH Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$109.39 +4.16 (+3.95%)

Closing price 04:00 PM Eastern

Extended Trading

$107.47 -1.92 (-1.76%)

As of 07:53 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Janux Therapeutics NASDAQ:JANX

$24.96 +0.69 (+2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$25.20 +0.24 (+0.96%)

As of 07:21 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Lantheus NASDAQ:LNTH

$53.79 -0.11 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$54.06 +0.27 (+0.51%)

As of 07:02 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$27.87 +0.75 (+2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$27.92 +0.05 (+0.20%)

As of 07:26 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time